cannabis indica

Canabinoides Sintéticos CP-x

termo de indexação original: CP-x Synthetic Cannabinoids

O que é Canabinoides Sintéticos CP-x

A série CP foi desenvolvida na Pfizer no fim dos anos 1970 e início dos 1980, na busca por analgésicos derivados de canabinoides sem efeito psicoativo.

O CP 55,940 é seu representante principal e tem importância histórica: foi com ele, marcado radioativamente, que Allyn Howlett e William Devane demonstraram em 1988 a existência de um receptor canabinoide no cérebro — a descoberta que abriu todo o campo.

Até hoje é o composto de referência em ensaios de ligação: a afinidade de um canabinoide novo costuma ser medida por quanto ele desloca o CP 55,940 do receptor.

No acervo

O acervo do Cannabis Indica reúne 97 estudos científicos que tocam o composto Canabinoides Sintéticos CP-x, publicados entre 1983 e 2023. Pela leitura automatizada, 67 (69%) foram classificados como favoráveis, 21 (22%) como inconclusivos e 9 (9%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é estudo em animais (32 estudos), seguido de metanálise (31). As condições mais associadas são Dor, Câncer e Efeitos Adversos da Cannabis.

Estudos indexados
97
Período coberto
1983–2023
Favoráveis
67 · 69%
Inconclusivos
21 · 22%
Desfavoráveis
9 · 9%
Termo original
CP-x Synthetic Cannabinoids

O acervo em números

Tipo de estudo

Estudo em Animais32
Metanálise31
Estudo Laboratorial27
Ensaio Clínico Duplo-Cego5
Ensaio Clínico2

Direção do resultado

Favorável67
Inconclusivo21
Desfavorável9

Por década

1980s3
1990s9
2000s22
2010s42
2020s21

97 estudos

Filtrar e buscar no acervo →
  1. 2023

    Cannabinoid receptor type 1 (CB1R) inhibits hypothalamic leptin signaling via β-arrestin1 in complex with TC-PTP and STAT3

  2. 2023

    The Effects of Peripubertal THC Exposure in Neurodevelopmental Rat Models of Psychopathology

  3. 2022

    A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment

    FavorávelMetanáliseDorCâncerAnsiedadeAnandamida (AEA)Tetraidrocanabinol (THC)+25
  4. 2022

    Differential activation of G protein‐mediated signaling by synthetic cannabinoid receptor agonists

  5. 2022

    In it together? The case for endocannabinoid–noradrenergic interactions in fear extinction

  6. 2022

    In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils

    FavorávelEstudo LaboratorialDorCâncerInflamaçãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+14
  7. 2022

    Involvement of spinal G-protein inwardly rectifying potassium (GIRK) channels in the enhanced antinociceptive effects of the activation of both μ-opioid and cannabinoid CB1 receptors

  8. 2022

    Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies

  9. 2022

    Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence

  10. 2022

    Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies

  11. 2022

    Synaptic changes induced by cannabinoid drugs and cannabis use disorder

  12. 2022

    Synthetic cannabinoid CP-55,940 induces apoptosis in a human skeletal muscle model via regulation of CB1 receptors and L-type Ca2+ channels

    FavorávelEstudo LaboratorialCâncerCâncer — Tecidos Moles
  13. 2022

    Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer?

  14. 2021

    Cannabinoids modulate food preference and consumption in Drosophila melanogaster

  15. 2021

    Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC

    FavorávelMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+17
  16. 2021

    Cannabis Use and Mental Illness: Understanding Circuit Dysfunction Through Preclinical Models

  17. 2021

    Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions

  18. 2021

    Systematic review of the impact of cannabinoids on neurobehavioral outcomes in preclinical models of traumatic and nontraumatic spinal cord injury

  19. 2020

    Age-dependent hormesis-like effects of the synthetic cannabinoid CP55940 in C57BL/6 mice

    InconclusivoEstudo em AnimaisCondições Geriátricas
  20. 2020

    Cannabinoid-profiled agents improve cell survival via reduction of oxidative stress and inflammation, and Nrf2 activation in a toxic model combining hyperglycemia+Aβ 1-42 peptide in rat hippocampal neurons

    FavorávelEstudo LaboratorialDoença de AlzheimerAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  21. 2020

    THC Regulates Tearing via Cannabinoid CB1 Receptors

    InconclusivoEstudo em AnimaisDorDor — OcularUveíteAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  22. 2019

    Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: impact of drug and fixed-dose ratio

    FavorávelEstudo em AnimaisDorDependência QuímicaDor — CrônicaCanabinoides Sintéticos WIN-x+3
  23. 2019

    Cannabichromene is a cannabinoid CB2 receptor agonist

  24. 2019

    Cannabinoids and Dementia: A Review of Clinical and Preclinical Data

  25. 2019

    Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?

  26. 2019

    The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species

  27. 2018

    Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal

    FavorávelEstudo em Animais
  28. 2018

    Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans

    DesfavorávelEnsaio Clínico Duplo-CegoDisfunção CognitivaCanabinoides Sintéticos AM-x
  29. 2018

    Cannabinoids, the Heart of the Matter.

  30. 2018

    The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain

  31. 2017

    Cannabinoid CB1/CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity‐based anorexia

  32. 2017

    Chronic Adolescent Δ9-Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment

  33. 2017

    Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis.

  34. 2016

    Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.

    FavorávelEstudo LaboratorialDoença de HuntingtonAnandamida (AEA)Tetraidrocanabinol (THC)+2
  35. 2016

    Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation.

    FavorávelEstudo em AnimaisDoença FalciformeAnandamida (AEA)Canabinoides Sintéticos JWH-x
  36. 2016

    Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting.

  37. 2016

    Cannabinoids, cannabinoid receptors and tinnitus

    DesfavorávelMetanáliseZumbidoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  38. 2016

    Comparing the effects of endogenous and synthetic cannabinoid receptor agonists on survival of gastric cancer cells.

  39. 2016

    Effects of cannabinoid receptor activation by CP55,940 on normal bladder function and irritation-induced bladder overactivity in non-awake anaesthetised rats

    FavorávelEstudo em AnimaisInfecção Urinária
  40. 2016

    Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.

  41. 2016

    Modulation of cellular redox homeostasis by the endocannabinoid system.

  42. 2015

    Cannabinoid inhibits HIV-1 Tat-stimulated adhesion of human monocyte-like cells to extracellular matrix proteins.

  43. 2015

    On The Effects Of CP 55-940 And Other Cannabinoid Receptor Agonists In C6 And U373 Cell Lines

  44. 2015

    Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection

  45. 2015

    The Effect of Phytocannabinoids on Airway Hyper-Responsiveness, Airway Inflammation, and Cough.

    FavorávelEstudo em AnimaisTosseTetraidrocanabinol (THC)Canabinoides Sintéticos AM-x+4
  46. 2015

    Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans

    DesfavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisAnsiedadeDisfunção CognitivaTetraidrocanabinol (THC)+2
  47. 2014

    Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system

  48. 2014

    Multiple Mechanistically Distinct Modes of Endocannabinoid Mobilization at Central Amygdala Glutamatergic Synapses

    FavorávelEstudo em AnimaisAnsiedadeTEPT2-Araquidonoilglicerol (2-AG)
  49. 2014

    Pharmacology, Toxicology, and Adverse Effects of Synthetic Cannabinoid Drugs

  50. 2013

    Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile

  51. 2013

    Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation.

  52. 2013

    Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling.

    InconclusivoEstudo em AnimaisAnsiedadeDepressãoEsquizofrenia
  53. 2013

    Mouse Models for Studying Pain In Sickle Disease: Effects of Strain, Age, and Acuteness

    FavorávelEstudo em AnimaisDoença FalciformeMonoacilglicerol Lipase (MAGL)
  54. 2013

    Repeated Low-Dose Administration of the Monoacylglycerol Lipase Inhibitor JZL184 Retains Cannabinoid Receptor Type 1–Mediated Antinociceptive and Gastroprotective Effects

  55. 2012

    "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans

  56. 2012

    Modulation of l-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids

    InconclusivoEstudo LaboratorialDorCâncerCanabinoides Sintéticos AM-xCanabinoides Sintéticos WIN-x+10
  57. 2011

    Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys

    InconclusivoEstudo em AnimaisDistoniaCanabinoides Sintéticos SR-x
  58. 2011

    Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance

    FavorávelEnsaio Clínico Duplo-CegoDorAnsiedadeNáusea e Vômito+5
  59. 2010

    Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease

    FavorávelMetanáliseInflamaçãoAnandamida (AEA)Tetraidrocanabinol (THC)+5
  60. 2010

    Do Cannabinoids have a therapeutic role in transplantation?

  61. 2010

    Endocannabinoids and Schizophrenia

  62. 2010

    Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids.

    FavorávelEstudo em AnimaisDoença Falciforme
  63. 2010

    The effects of the synthetic cannabinoid receptor agonists, WIN55,212-2 and CP55,940, on salicylate-induced tinnitus in rats

    InconclusivoEstudo em AnimaisZumbidoCanabinoides Sintéticos WIN-x
  64. 2009

    (Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells

    FavorávelEstudo LaboratorialVirodamina (O-AEA)
  65. 2009

    Atypical Responsiveness of the Orphan Receptor GPR55 to Cannabinoid Ligands

    FavorávelEstudo LaboratorialObesidade
  66. 2009

    Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation

  67. 2009

    Withdrawal Phenomena and Dependence Syndrome After the Consumption of "Spice Gold"

  68. 2008

    Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.

    FavorávelEstudo em AnimaisHepatiteAnandamida (AEA)Hidrolase de Amidas de Ácidos Graxos (FAAH)+3
  69. 2008

    Cannabinoids Inhibit HIV-1 Gp120-Mediated Insults in Brain Microvascular Endothelial Cells

    FavorávelEstudo LaboratorialHIV/AIDS2-Araquidonoilglicerol (2-AG)Canabinoides Sintéticos AM-x+1
  70. 2008

    Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes

  71. 2008

    Reciprocal influences of CB1 cannabinoid receptor agonists on ERK and JNK signalling in N1E-115 cells

    InconclusivoEstudo LaboratorialCâncerCâncer — NeuroblastomaCanabinoides Sintéticos HU-x
  72. 2007

    Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors.

    FavorávelEstudo em AnimaisEsclerose MúltiplaCanabinoides Sintéticos WIN-x
  73. 2007

    Interactions Between Endocannabinoids and Stress-Induced Decreased Sensitivity to Natural Reward

  74. 2007

    Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew

  75. 2007

    The Cannabinoid Delta-9-tetrahydrocannabinol Mediates Inhibition of Macrophage Chemotaxis to RANTES/CCL5 through the CB2 Receptor

  76. 2007

    The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.

    FavorávelEnsaio ClínicoEsclerose MúltiplaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+4
  77. 2007

    Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells

    FavorávelEstudo LaboratorialInflamaçãoCOVID-19Virodamina (O-AEA)
  78. 2005

    Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus.

  79. 2005

    Therapeutic opportunities through modulation of the endocannabinoid system

  80. 2004

    Cannabinoids Prevent the Acute Hyperthermia and Partially Protect Against the 5-HT Depleting Effects of MDMA ("Ecstasy") in Rats

  81. 2004

    Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors

    FavorávelEstudo LaboratorialTetraidrocanabinol (THC)Canabinoides Sintéticos WIN-x+3
  82. 2004

    Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis

    FavorávelEstudo em Animais2-Araquidonoilglicerol (2-AG)Canabinoides Sintéticos AM-x+1
  83. 2003

    An Endogenous Cannabinoid Tone Attenuates Cholera Toxin-Induced Fluid Accumulation in Mice

    InconclusivoEstudo em AnimaisDiarreiaCóleraAnandamida (AEA)
  84. 2001

    Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.

  85. 2000

    Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide

    FavorávelEstudo em AnimaisDorDor — AgudaAnandamida (AEA)
  86. 1999

    Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide.

  87. 1997

    Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells

    InconclusivoEstudo LaboratorialCâncerCâncer — NeuroblastomaCanabinoides Sintéticos SR-x
  88. 1996

    Determination of the cannabinoid receptors in mouse x rat hybridoma NG108-15 cells and rat GH4C1 cells

  89. 1995

    Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors

    InconclusivoEstudo LaboratorialAnandamida (AEA)Tetraidrocanabinol (THC)+3
  90. 1995

    The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling

    DesfavorávelEstudo LaboratorialEfeitos Adversos da CannabisGestaçãoAnandamida (AEA)Tetraidrocanabinol (THC)+1
  91. 1993

    Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells

  92. 1993

    Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.

    FavorávelEstudo LaboratorialDoença de Huntington
  93. 1993

    Pharmacological evaluation of iodo and nitro analogs of delta 8-THC and delta 9-THC

    InconclusivoEstudo em AnimaisDelta-8-THC
  94. 1992

    Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism.

    InconclusivoEstudo LaboratorialCâncerCâncer — NeuroblastomaTetraidrocanabinol (THC)
  95. 1985

    Antiemetic Efficacy of Levonantradol Compared to delta-9-tetrahydrocannabinol for Chemotherapy-Induced Nausea and Vomiting

    FavorávelEnsaio Clínico Duplo-CegoNáusea e VômitoNáusea e Vômito por Quimioterapia
  96. 1985

    Phase 1 Trial of Levonantradol in Chemotherapy-Induced Emesis

    FavorávelEnsaio ClínicoNáusea e VômitoNáusea e Vômito por Quimioterapia
  97. 1983

    A randomised multicentre single blind comparison of a cannabinoid anti-emetic (Levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy

    FavorávelEnsaio Clínico Duplo-CegoNáusea e VômitoNáusea e Vômito por Quimioterapia

Continue por aqui

Perguntas frequentes

Quantos estudos sobre canabinoides sintéticos cp-x estão indexados no acervo?
São 97 estudos, publicados entre 1983 e 2023. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Estudo em Animais: 32 · Metanálise: 31 · Estudo Laboratorial: 27 · Ensaio Clínico Duplo-Cego: 5 · Ensaio Clínico: 2. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 67 favoráveis, 21 inconclusivos e 9 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Canabinoides Sintéticos CP-x — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/canabinoide/canabinoides-sinteticos-cp-x/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Canabinoides Sintéticos CP-x — estudos científicos sobre cannabis. https://cannabisindica.com.br/canabinoide/canabinoides-sinteticos-cp-x/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.